Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Be an adult ≥18 and ≤ 75 years of age at the screening visit (Screening) with atopic dermatitis according to American Academy of Dermatology Consensus Criteria, (Eichenfield 2014)~2. Present for at least 1 year prior to the baseline visit (Baseline) with an inadequate response, in the judgement of the Investigator, to AD treatment with a topical regimen of corticosteroids, phosphodiesterase inhibitors or calcineurin inhibitors, or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effect or safety risks)~3. Investigator Global Assessment (IGA) score ≥ 3 at Screening and Baseline.~4. Eczema Area and Severity Index (EASI) score ≥ 16 at Screening and Baseline~5. Body Surface Area (BSA) for total AD involvement ≥ 10% at Screening and Baseline~6. Able and willing to apply a stable dose of a bland emollient twice a day to affected areas for at least 7 days before Baseline and to continue for the duration of the study~7. Females of child-bearing potential (FCBP) and males who have not undergone a vasectomy must abstain from heterosexual activities or agree to use effective contraception throughout the entire study period.~Exclusion Criteria:~1. Have any of the following laboratory abnormalities at Screening:~   1. Hemoglobin ≤ 90% of the lower limit of normal range (LLN)~  2. White blood cell (WBC) below the LLN~  3. Neutrophil count below the LLN~  4. Platelet count below the LLN~2. Have undergone treatment with any of the following:~   1. Topical agents such as corticosteroids, phosphodiesterase (PDE) inhibitors, Janus kinase (JAK) inhibitors, tacrolimus or pimecrolimus within 1 week prior to Baseline. Note that low to medium potency topical corticosteroids (TCS) are permitted after randomization to treat AD flares~  2. Prior treatment with dupilumab or any antibody against IL-4Rα or IL-13~  3. Systemic treatment for AD or other condition with steroids or other immunosuppressive/immunomodulating substances, e.g., cyclosporine, mycophenolate-mofetil, azathioprine, methotrexate or oral Janus kinase (JAK) inhibitors within 4 weeks prior to Baseline. Use of steroid inhalers and nasal corticosteroids is allowed.~  4. Cell depleting agents, e.g. rituximab, within 6 months of Baseline or treatment with other biologics within 5 half-lives (if known) or 3 months prior to baseline visit, whichever is longer~  5. Phototherapy (narrow band ultraviolet B \[NBUVB\], ultraviolet B \[UVB\], ultraviolet A1 \[UVA1\], psoralen + ultraviolet A \[PUVA\]), tanning beds, or any other light emitting device (LED), within 4 weeks of Baseline~  6. ≥ 2 bleach baths within 2 weeks of Baseline~  7. Prescription emollient to treat AD (e.g. Atopiclair®, MimyX®, Epicerum®, etc.) within 2 weeks of Baseline~  8. Any investigational drug within 30 days or within 5 half-lives, whichever is longer, before Baseline.~  9. Live (attenuated) vaccine within 8 weeks of Baseline.~  10. Treatment with systemic traditional Chinese medicine (TCM) or herbal medications within 4 weeks before Baseline or treatment with topical TCM or herbal medications within 1 week before Baseline visit~3. Have any of the following:~   1. Infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before Baseline, or superficial skin infection, such as impetigo, within 2 weeks before the Baseline (subjects may be rescreened after the infection has resolved)~  2. A history of parasitic infection (e.g. helminth), within 6 months of Baseline~  3. Per investigator judgement, known or suspected history of immunosuppression within 6 months of Baseline, including a history of invasive opportunistic infections, such as aspergillosis, coccidioidomycosis, histoplasmosis, human immunodeficiency virus (HIV), listeriosis, pneumocystosis, or tuberculosis, despite infection resolution; or unusually frequent, recurrent or prolonged infections.~  4. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC)~  5. A history of malignancy with the following exceptions: completely treated carcinoma in situ of cervix or non-metastatic squamous or basal cell carcinoma of the skin~  6. Positive results at Screening for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody with positive HCV RNA polymerase chain reaction; positive HIV serology at screening~  7. An allergy to L-histidine, trehalose or Tween (polysorbate) 80~4. Women must not be pregnant, planning to become pregnant or breast-feed during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CBP-201 Dose 1 (Type: EXPERIMENTAL): CBP-201 Dose 1 subcutaneous (SC) injection
- CBP-201 Dose 2 (Type: EXPERIMENTAL): CBP-201 Dose 2 subcutaneous (SC) injection
- CBP-201 Dose 3 (Type: EXPERIMENTAL): CBP-201 Dose 3 subcutaneous (SC) injection
- placebo (Type: PLACEBO_COMPARATOR): subcutaneous (SC) injection

Based on this trial design, predict the completion outcome and termination type (if applicable).